Compare Novo Nordisk A/S (NVO) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Vanguard Real Estate Index Fund ETF — how do they compare? Novo Nordisk A/S trades at $45.1 (market cap $198.57B), while Vanguard Real Estate Index Fund ETF trades at $95.14. The key difference: Novo Nordisk A/S pays a 4.03% dividend while Vanguard Real Estate Index Fund ETF pays none, and Vanguard Real Estate Index Fund ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | VNQ | |
|---|---|---|
Market Cap | $198.57B | — |
Sector | Health | — |
52-Week High | $63.98 | $100.95 |
52-Week Low | $35.29 | $87.00 |
Enterprise Value | $213.37B | — |
Dividend Yield | 4.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
VNQ trades at $95.92, down 0.1% on the day, with technical indicators showing a bearish trend as moving averages signal selling pressure while oscillators remain neutral. The ETF faces headwinds from elevated interest rates impacting real estate valuations, though some analysts see mispricing opportunities in quality REITs during this downturn. Recent institutional selling activity and mixed media sentiment reflect ongoing sector challenges.
The outlook remains cautious as high rates pressure REIT valuations, but selective opportunities exist in digital infrastructure and quality names. Key risks include prolonged high interest rates, economic slowdowns affecting property demand, and competition from alternative income ETFs. Investors should focus on REITs with strong fundamentals and growth potential in evolving sectors like AI infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
